| Product Code: ETC6741640 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Dopamine Agonist Drug Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Dopamine Agonist Drug Market Revenues & Volume, 2021 & 2031F |
3.3 China Dopamine Agonist Drug Market - Industry Life Cycle |
3.4 China Dopamine Agonist Drug Market - Porter's Five Forces |
3.5 China Dopamine Agonist Drug Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 China Dopamine Agonist Drug Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 China Dopamine Agonist Drug Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.8 China Dopamine Agonist Drug Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 China Dopamine Agonist Drug Market Revenues & Volume Share, By End- Users, 2021 & 2031F |
3.10 China Dopamine Agonist Drug Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 China Dopamine Agonist Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurological disorders in China |
4.2.2 Growing geriatric population in China |
4.2.3 Rising healthcare expenditure in China |
4.3 Market Restraints |
4.3.1 Stringent regulatory approval process for dopamine agonist drugs in China |
4.3.2 High competition from existing and new market players |
5 China Dopamine Agonist Drug Market Trends |
6 China Dopamine Agonist Drug Market, By Types |
6.1 China Dopamine Agonist Drug Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 China Dopamine Agonist Drug Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 China Dopamine Agonist Drug Market Revenues & Volume, By Non-Ergoline Dopamine Agonists, 2021- 2031F |
6.1.4 China Dopamine Agonist Drug Market Revenues & Volume, By Ergot-Derived Dopamine Agonists, 2021- 2031F |
6.1.5 China Dopamine Agonist Drug Market Revenues & Volume, By Recombinant Factor VIII, 2021- 2031F |
6.1.6 China Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.2 China Dopamine Agonist Drug Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 China Dopamine Agonist Drug Market Revenues & Volume, By Parkinson's Disease, 2021- 2031F |
6.2.3 China Dopamine Agonist Drug Market Revenues & Volume, By Restless Leg Syndrome, 2021- 2031F |
6.2.4 China Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.3 China Dopamine Agonist Drug Market, By Drugs |
6.3.1 Overview and Analysis |
6.3.2 China Dopamine Agonist Drug Market Revenues & Volume, By Carbidopa and Levodopa, 2021- 2031F |
6.3.3 China Dopamine Agonist Drug Market Revenues & Volume, By Ropinirole, 2021- 2031F |
6.3.4 China Dopamine Agonist Drug Market Revenues & Volume, By Pramipexole, 2021- 2031F |
6.3.5 China Dopamine Agonist Drug Market Revenues & Volume, By Cabergoline, 2021- 2031F |
6.3.6 China Dopamine Agonist Drug Market Revenues & Volume, By Bromocriptine, 2021- 2031F |
6.3.7 China Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.4 China Dopamine Agonist Drug Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 China Dopamine Agonist Drug Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 China Dopamine Agonist Drug Market Revenues & Volume, By Injectable, 2021- 2031F |
6.5 China Dopamine Agonist Drug Market, By End- Users |
6.5.1 Overview and Analysis |
6.5.2 China Dopamine Agonist Drug Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 China Dopamine Agonist Drug Market Revenues & Volume, By Homecare, 2021- 2031F |
6.5.4 China Dopamine Agonist Drug Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.5 China Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.6 China Dopamine Agonist Drug Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 China Dopamine Agonist Drug Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.6.3 China Dopamine Agonist Drug Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
7 China Dopamine Agonist Drug Market Import-Export Trade Statistics |
7.1 China Dopamine Agonist Drug Market Export to Major Countries |
7.2 China Dopamine Agonist Drug Market Imports from Major Countries |
8 China Dopamine Agonist Drug Market Key Performance Indicators |
8.1 Number of clinical trials for dopamine agonist drugs in China |
8.2 Adoption rate of dopamine agonist drugs in major hospitals and clinics in China |
8.3 Investment in research and development for new dopamine agonist drug formulations in China |
9 China Dopamine Agonist Drug Market - Opportunity Assessment |
9.1 China Dopamine Agonist Drug Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 China Dopamine Agonist Drug Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 China Dopamine Agonist Drug Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.4 China Dopamine Agonist Drug Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 China Dopamine Agonist Drug Market Opportunity Assessment, By End- Users, 2021 & 2031F |
9.6 China Dopamine Agonist Drug Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 China Dopamine Agonist Drug Market - Competitive Landscape |
10.1 China Dopamine Agonist Drug Market Revenue Share, By Companies, 2024 |
10.2 China Dopamine Agonist Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here